title: Clinical observation on the efficacy of CyberKnife for primary or metastatic retroperitoneal tumours.
abstract: The aim of the paper is to evaluate the efficacy of CyberKnife® for the treatment of primary or metastatic retroperitoneal tumours. Twenty-eight patients were treated. The prescription isodose line (median, 78%; range, 70-84%) covered the planning target volume at a total dose of 2000-6000 cGy (median, 4500 cGy) and a biologically effective dose of 3750-10,080 cGy (median, 7680 cGy) in 2-10 fractions (median, five fractions). The results showed that the complete response, partial response, stable disease, and progressive disease rates were 43% (12/28), 36% (10/28), 18% (5/28), and 4% (1/28) respectively. The overall response rate was 96%. The 1-, 2- and 3-year local control rates were 92%, 86%, and 86% respectively. The 1-, 2- and 3-year overall survival rates were 60%, 49%, and 49% respectively. No significant difference was found between local progression-free survival and overall survival. Moreover, if a patient only had metastases in the retroperitoneum and local control was effective, there was no significant difference between local progression-free survival and overall progression-free survival. In conclusion, CyberKnife treatment for retroperitoneal tumours resulted in high response rates with minimal side effects. All radiation-induced side effects were well tolerated.
authors: Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
authors: H-Q
authors: HQ
authors: Zhuang
authors: Z-Y
authors: ZY
authors: Yuan
authors: Y-C
authors: YC
authors: Song
authors: J
authors: J
authors: Wang
authors: L-J
authors: LJ
authors: Zhao
authors: P
authors: P
authors: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011829:Radiation Dosage; D016634:Radiosurgery; D012186:Retroperitoneal Neoplasms / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D016019:Survival Analysis; D055815:Young Adult
keywords: CyberKnife; clinical efficacy; metastatic; primary; retroperitoneal tumours